e-therapeutics ETXPF Stock
e-therapeutics Price Chart
e-therapeutics ETXPF Financial and Trading Overview
| e-therapeutics stock price | 0.13 USD |
| Previous Close | 0.19 USD |
| Open | 0.19 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.19 - 0.19 USD |
| 52 Week Range | 0.19 - 0.26 USD |
| Volume | 5K USD |
| Avg. Volume | 84 USD |
| Market Cap | 158.59M USD |
| Beta (5Y Monthly) | 0.32567 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.02 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ETXPF Valuation Measures
| Enterprise Value | 79.31M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 333.8796 |
| Price/Book (mrq) | 3.3333333 |
| Enterprise Value/Revenue | 166.971 |
| Enterprise Value/EBITDA | -7.797 |
Trading Information
e-therapeutics Stock Price History
| Beta (5Y Monthly) | 0.32567 |
| 52-Week Change | -1.55% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.26 USD |
| 52 Week Low | 0.19 USD |
| 50-Day Moving Average | 0.19 USD |
| 200-Day Moving Average | 0.22 USD |
ETXPF Share Statistics
| Avg. Volume (3 month) | 84 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 582.66M |
| Float | 156.69M |
| Short Ratio | N/A |
| % Held by Insiders | 59.47% |
| % Held by Institutions | 28.93% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | January 31, 2023 |
| Most Recent Quarter (mrq) | January 31, 2023 |
| Next Fiscal Year End | January 31, 2024 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2155.57% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.95% |
| Return on Equity (ttm) | -27.22% |
Income Statement
| Revenue (ttm) | 475K USD |
| Revenue Per Share (ttm) | 0.001 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -10172000 USD |
| Net Income Avi to Common (ttm) | -8274000 USD |
| Diluted EPS (ttm) | -0.02 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 31.69M USD |
| Total Cash Per Share (mrq) | 0.05 USD |
| Total Debt (mrq) | 295K USD |
| Total Debt/Equity (mrq) | 0.89 USD |
| Current Ratio (mrq) | 21.304 |
| Book Value Per Share (mrq) | 0.057 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -8011000 USD |
| Levered Free Cash Flow (ttm) | -5903750 USD |
Profile of e-therapeutics
| Country | United States |
| State | N/A |
| City | London |
| Address | 4 Kingdom Street |
| ZIP | W2 6BD |
| Phone | 44 20 4551 8888 |
| Website | https://www.etherapeutics.co.uk |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 38 |
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.
Q&A For e-therapeutics Stock
What is a current ETXPF stock price?
e-therapeutics ETXPF stock price today per share is 0.13 USD.
How to purchase e-therapeutics stock?
You can buy ETXPF shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for e-therapeutics?
The stock symbol or ticker of e-therapeutics is ETXPF.
Which industry does the e-therapeutics company belong to?
The e-therapeutics industry is Biotechnology.
How many shares does e-therapeutics have in circulation?
The max supply of e-therapeutics shares is 584.33M.
What is e-therapeutics Price to Earnings Ratio (PE Ratio)?
e-therapeutics PE Ratio is now.
What was e-therapeutics earnings per share over the trailing 12 months (TTM)?
e-therapeutics EPS is -0.02 USD over the trailing 12 months.
Which sector does the e-therapeutics company belong to?
The e-therapeutics sector is Healthcare.